I think my central point remains that there is a risk that we get into a potentially perpetual cycle of approvals under section 23 if the vaccine changes to such a degree that a new application is warranted. Therefore, we may never—that's a slightly far-reaching sort of conclusion—actually approve a COVID vaccine under sections 20 to 22, and that was never the intention of this section. It's an unusual situation, I think, where because of the potential rapid mutation of a virus, the medicine itself changes to such a degree that it's no longer applicable to dispense it under the gazetting under section 23. I simply raise it as a policy question for the ministry, because it may well be that we need a third path of approvals.